Dermatologic manifestations of Crohn disease in children: Response to infliximab
Identifieur interne : 009272 ( Main/Exploration ); précédent : 009271; suivant : 009273Dermatologic manifestations of Crohn disease in children: Response to infliximab
Auteurs : Subra Kugathasan [États-Unis] ; Adrian Miranda [États-Unis] ; James Nocton [États-Unis] ; Beth A. Drolet [États-Unis] ; Carolyn Raasch [États-Unis] ; David G. Binion [États-Unis]Source :
- Journal of pediatric gastroenterology and nutrition [ 0277-2116 ] ; 2003.
Descripteurs français
- KwdFr :
- Adolescent, Anticorps monoclonaux (effets indésirables), Anticorps monoclonaux (usage thérapeutique), Enfant, Humains, Infliximab, Lymphoedème (traitement médicamenteux), Lymphoedème (étiologie), Maladie de Crohn (), Mâle, Produits dermatologiques (effets indésirables), Produits dermatologiques (usage thérapeutique), Pyodermie phadégénique (traitement médicamenteux), Pyodermie phadégénique (étiologie), Résultat thérapeutique, Érythème noueux (traitement médicamenteux), Érythème noueux (étiologie).
- MESH :
- effets indésirables : Anticorps monoclonaux, Produits dermatologiques.
- traitement médicamenteux : Lymphoedème, Pyodermie phadégénique, Érythème noueux.
- usage thérapeutique : Anticorps monoclonaux, Produits dermatologiques.
- étiologie : Lymphoedème, Pyodermie phadégénique, Érythème noueux.
- Pascal (Inist)
- Wicri :
- topic : Enfant.
English descriptors
- KwdEn :
- Adolescent, Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (therapeutic use), Anticytokine, Case study, Chemotherapy, Child, Complication, Crohn Disease (complications), Crohn disease, Dermatologic Agents (adverse effects), Dermatologic Agents (therapeutic use), Erythema Nodosum (drug therapy), Erythema Nodosum (etiology), Erythema nodosum, Humans, Infliximab, Lymphedema, Lymphedema (drug therapy), Lymphedema (etiology), Male, Pyoderma Gangrenosum (drug therapy), Pyoderma Gangrenosum (etiology), Pyoderma gangrenosum, Treatment Outcome, Treatment efficiency.
- MESH :
- chemical , adverse effects : Antibodies, Monoclonal, Dermatologic Agents.
- chemical , therapeutic use : Antibodies, Monoclonal, Dermatologic Agents.
- complications : Crohn Disease.
- drug therapy : Erythema Nodosum, Lymphedema, Pyoderma Gangrenosum.
- etiology : Erythema Nodosum, Lymphedema, Pyoderma Gangrenosum.
- Adolescent, Child, Humans, Infliximab, Male, Treatment Outcome.
Abstract
Dermatologic extraintestinal manifestations of Crohn disease may be refractory to treatment with corticosteroids and immunomodulators. The authors describe four children with Crohn disease with dermatologic manifestations: pyoderma gangrenosum, orofacial involvement, erythema nodosum, and idiopathic lymphedema. These dermatologic conditions were unresponsive to conventional therapy but had rapid and sustained response to the anti-TNF-α antibody infliximab. No adverse reactions occurred. Infliximab should be considered for treating the extraintestinal dermatologic manifestations of Crohn disease in children.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000667
- to stream PascalFrancis, to step Curation: 000293
- to stream PascalFrancis, to step Checkpoint: 000685
- to stream Main, to step Merge: 009591
- to stream PubMed, to step Corpus: 004214
- to stream PubMed, to step Curation: 004214
- to stream PubMed, to step Checkpoint: 004214
- to stream Ncbi, to step Merge: 000E20
- to stream Ncbi, to step Curation: 000E20
- to stream Ncbi, to step Checkpoint: 000E20
- to stream Main, to step Merge: 009211
- to stream Main, to step Curation: 009272
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dermatologic manifestations of Crohn disease in children: Response to infliximab</title>
<author><name sortKey="Kugathasan, Subra" sort="Kugathasan, Subra" uniqKey="Kugathasan S" first="Subra" last="Kugathasan">Subra Kugathasan</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Children's Hospital of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miranda, Adrian" sort="Miranda, Adrian" uniqKey="Miranda A" first="Adrian" last="Miranda">Adrian Miranda</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Children's Hospital of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nocton, James" sort="Nocton, James" uniqKey="Nocton J" first="James" last="Nocton">James Nocton</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Division of Pediatric Rheumatology, Department of Pediatrics, Children's Hospital of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Drolet, Beth A" sort="Drolet, Beth A" uniqKey="Drolet B" first="Beth A." last="Drolet">Beth A. Drolet</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Dermatology, Medical College of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Raasch, Carolyn" sort="Raasch, Carolyn" uniqKey="Raasch C" first="Carolyn" last="Raasch">Carolyn Raasch</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Children's Hospital of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Binion, David G" sort="Binion, David G" uniqKey="Binion D" first="David G." last="Binion">David G. Binion</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Gastroenterology and Hepatology, Department of Medicine, Medical College of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0010819</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0010819 INIST</idno>
<idno type="RBID">Pascal:04-0010819</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000667</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000293</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000685</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000685</idno>
<idno type="wicri:doubleKey">0277-2116:2003:Kugathasan S:dermatologic:manifestations:of</idno>
<idno type="wicri:Area/Main/Merge">009591</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12883301</idno>
<idno type="wicri:Area/PubMed/Corpus">004214</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004214</idno>
<idno type="wicri:Area/PubMed/Curation">004214</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004214</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004214</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004214</idno>
<idno type="wicri:Area/Ncbi/Merge">000E20</idno>
<idno type="wicri:Area/Ncbi/Curation">000E20</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E20</idno>
<idno type="wicri:doubleKey">0277-2116:2003:Kugathasan S:dermatologic:manifestations:of</idno>
<idno type="wicri:Area/Main/Merge">009211</idno>
<idno type="wicri:Area/Main/Curation">009272</idno>
<idno type="wicri:Area/Main/Exploration">009272</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dermatologic manifestations of Crohn disease in children: Response to infliximab</title>
<author><name sortKey="Kugathasan, Subra" sort="Kugathasan, Subra" uniqKey="Kugathasan S" first="Subra" last="Kugathasan">Subra Kugathasan</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Children's Hospital of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miranda, Adrian" sort="Miranda, Adrian" uniqKey="Miranda A" first="Adrian" last="Miranda">Adrian Miranda</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Children's Hospital of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nocton, James" sort="Nocton, James" uniqKey="Nocton J" first="James" last="Nocton">James Nocton</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Division of Pediatric Rheumatology, Department of Pediatrics, Children's Hospital of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Drolet, Beth A" sort="Drolet, Beth A" uniqKey="Drolet B" first="Beth A." last="Drolet">Beth A. Drolet</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Dermatology, Medical College of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Raasch, Carolyn" sort="Raasch, Carolyn" uniqKey="Raasch C" first="Carolyn" last="Raasch">Carolyn Raasch</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Children's Hospital of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Binion, David G" sort="Binion, David G" uniqKey="Binion D" first="David G." last="Binion">David G. Binion</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Gastroenterology and Hepatology, Department of Medicine, Medical College of Wisconsin</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of pediatric gastroenterology and nutrition</title>
<title level="j" type="abbreviated">J. pediatr. gastroenterol. nutr.</title>
<idno type="ISSN">0277-2116</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of pediatric gastroenterology and nutrition</title>
<title level="j" type="abbreviated">J. pediatr. gastroenterol. nutr.</title>
<idno type="ISSN">0277-2116</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Antibodies, Monoclonal (adverse effects)</term>
<term>Antibodies, Monoclonal (therapeutic use)</term>
<term>Anticytokine</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Child</term>
<term>Complication</term>
<term>Crohn Disease (complications)</term>
<term>Crohn disease</term>
<term>Dermatologic Agents (adverse effects)</term>
<term>Dermatologic Agents (therapeutic use)</term>
<term>Erythema Nodosum (drug therapy)</term>
<term>Erythema Nodosum (etiology)</term>
<term>Erythema nodosum</term>
<term>Humans</term>
<term>Infliximab</term>
<term>Lymphedema</term>
<term>Lymphedema (drug therapy)</term>
<term>Lymphedema (etiology)</term>
<term>Male</term>
<term>Pyoderma Gangrenosum (drug therapy)</term>
<term>Pyoderma Gangrenosum (etiology)</term>
<term>Pyoderma gangrenosum</term>
<term>Treatment Outcome</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Anticorps monoclonaux (effets indésirables)</term>
<term>Anticorps monoclonaux (usage thérapeutique)</term>
<term>Enfant</term>
<term>Humains</term>
<term>Infliximab</term>
<term>Lymphoedème (traitement médicamenteux)</term>
<term>Lymphoedème (étiologie)</term>
<term>Maladie de Crohn ()</term>
<term>Mâle</term>
<term>Produits dermatologiques (effets indésirables)</term>
<term>Produits dermatologiques (usage thérapeutique)</term>
<term>Pyodermie phadégénique (traitement médicamenteux)</term>
<term>Pyodermie phadégénique (étiologie)</term>
<term>Résultat thérapeutique</term>
<term>Érythème noueux (traitement médicamenteux)</term>
<term>Érythème noueux (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Dermatologic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Dermatologic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Crohn Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Erythema Nodosum</term>
<term>Lymphedema</term>
<term>Pyoderma Gangrenosum</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Produits dermatologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Erythema Nodosum</term>
<term>Lymphedema</term>
<term>Pyoderma Gangrenosum</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphoedème</term>
<term>Pyodermie phadégénique</term>
<term>Érythème noueux</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Produits dermatologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term>
<term>Pyodermie phadégénique</term>
<term>Érythème noueux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Child</term>
<term>Humans</term>
<term>Infliximab</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adolescent</term>
<term>Enfant</term>
<term>Entérite Crohn</term>
<term>Complication</term>
<term>Humains</term>
<term>Infliximab</term>
<term>Maladie de Crohn</term>
<term>Mâle</term>
<term>Pyodermite phagédénique</term>
<term>Erythème noueux</term>
<term>Lymphoedème</term>
<term>Efficacité traitement</term>
<term>Chimiothérapie</term>
<term>Infliximab</term>
<term>Anticytokine</term>
<term>Etude cas</term>
<term>Enfant</term>
<term>Résultat thérapeutique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enfant</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dermatologic extraintestinal manifestations of Crohn disease may be refractory to treatment with corticosteroids and immunomodulators. The authors describe four children with Crohn disease with dermatologic manifestations: pyoderma gangrenosum, orofacial involvement, erythema nodosum, and idiopathic lymphedema. These dermatologic conditions were unresponsive to conventional therapy but had rapid and sustained response to the anti-TNF-α antibody infliximab. No adverse reactions occurred. Infliximab should be considered for treating the extraintestinal dermatologic manifestations of Crohn disease in children.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Wisconsin</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Wisconsin"><name sortKey="Kugathasan, Subra" sort="Kugathasan, Subra" uniqKey="Kugathasan S" first="Subra" last="Kugathasan">Subra Kugathasan</name>
</region>
<name sortKey="Binion, David G" sort="Binion, David G" uniqKey="Binion D" first="David G." last="Binion">David G. Binion</name>
<name sortKey="Drolet, Beth A" sort="Drolet, Beth A" uniqKey="Drolet B" first="Beth A." last="Drolet">Beth A. Drolet</name>
<name sortKey="Miranda, Adrian" sort="Miranda, Adrian" uniqKey="Miranda A" first="Adrian" last="Miranda">Adrian Miranda</name>
<name sortKey="Nocton, James" sort="Nocton, James" uniqKey="Nocton J" first="James" last="Nocton">James Nocton</name>
<name sortKey="Raasch, Carolyn" sort="Raasch, Carolyn" uniqKey="Raasch C" first="Carolyn" last="Raasch">Carolyn Raasch</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009272 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009272 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:04-0010819 |texte= Dermatologic manifestations of Crohn disease in children: Response to infliximab }}
![]() | This area was generated with Dilib version V0.6.31. | ![]() |